Results 151 to 160 of about 44,348 (178)

Effectiveness and Safety of Rituximab in Patients with Refractory Juvenile Idiopathic Arthritis: A Tertiary Center Experience. [PDF]

Pharmaceuticals (Basel)
Alexeeva EI, Kondrateva NM, Dvoryakovskaya TM, Kudlay DA, Kriulin IA, Botova MS, Tsulukiya IT, Krekhova EA, Shingarova MS, Kokina MY, Fetisova AN, Kriulina TY, Isaeva KB, Chomakhidze AM, Chibisova CV, Kostik MM.   +15 more
europepmc   +1 more source

Reduced IgM natural autoantibody levels against heat shock proteins are associated with disease severity in juvenile idiopathic arthritis. [PDF]

Front Immunol
Mosdósi B, Mátis V, Győri Á, Peti P, Erdő-Bonyár S, Berki T, Simon D.   +6 more
europepmc   +1 more source

Developing a patient-educator program for adolescents with juvenile arthritis: exploring motivation sources, barriers, and facilitators. [PDF]

Can Med Educ J
Morin MP, Shah AQ, Mylopoulos M, Pomey MP, Bowen F, Grierson L, Bourque CJ.   +6 more
europepmc   +1 more source

Proceedings of the 33rd European Paediatric Rheumatology Congress. [PDF]

Pediatr Rheumatol Online J
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Juvenile Idiopathic Arthritis

Nature Reviews Disease Primers, 2022
Alberto Martini, Kimme L. Hyrich, Nicolino Ruperto   +2 more
exaly  

Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy, and Safety Trial

Lancet, The, 2023
Ralf Trauzeddel, Inmaculada Calvo Penadés, Zhixuan Zhou   +2 more
exaly